BELGRADE, MT / ACCESSWIRE / May 22, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will participate in the 21st Annual Craig-Hallum Institutional Investor Conference on May 29 in Minneapolis.
The conference is a multi-industry event featuring more than 130 public companies. The format includes one-on-one and small group meetings. To schedule a meeting with management, please contact Brett Maas at xtnt@haydenir.com or your Craig Hallum representative.
In conjunction with hosting one-on-one and small group meetings with investors, the Company’s investor presentation is accessible by visiting the “Investors” section of the Company’s website at https://investor.xtantmedical.com/.
About Xtant Medical Holdings, Inc.
Xtant Medical’s mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (https://xtantmedical.com/) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.
The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.
Investor Relations Contact
Brett Maas • Managing Partner, Hayden IR
brett@haydenir.com • (646) 536-7331
SOURCE: Xtant Medical Holdings, Inc.
View the original press release on accesswire.com
FRONTIER2 data presented at ISTH 2024 showed that up to 95% of people, who had…
Pemvidutide elicited significant weight loss and decreases in pro-inflammatory serum lipids associated with atherogenesis and…
TAIPEI, June 22, 2024 /PRNewswire/ -- The prestigious 2024 Tang Prize Laureates have been announced,…
Afrezza® Afrezza® (insulin human) Inhalation Powder. Study proves inhaled insulin is as effective as usual…
PURCHASE, NY, June 21, 2024 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader…
TERN-501 significantly improved the efficacy of a GLP-1 receptor agonist by normalizing energy expenditure, resulting…